Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis

Journal of Cardiovascular Translational Research

Volumn 8, Issue 4, 2015, Pages 264-268

  Halushka, Marc K ^a   Eng, George ^b   Collins, A Bernard ^b   Judge, Daniel P ^a   Semigran, Marc J ^b   Stone, James R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyloid; Classification; Diagnostic test; Immunoglobulin light chain; Transthyretin

Indexed keywords

AMYLOID A PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PREALBUMIN; BIOLOGICAL MARKER; SERUM AMYLOID A;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEART AMYLOIDOSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BLOOD; CARDIOMYOPATHIES; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HEART MUSCLE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BALTIMORE; BIOMARKERS; BOSTON; CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; SERUM AMYLOID A PROTEIN;

EID: 84931561251     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-015-9628-2     Document Type: Article

References (24)

1. Shah, K. B., Inoue, Y., & Mehra, M. R. (2006). Amyloidosis and the heart: a comprehensive review. Archives of Internal Medicine, 166, 1805–1813.
2. Dey, B. R., Chung, S. S., Spitzer, T. R., Zheng, H., Macgillivray, T. E., Seldin, D. C., McAfee, S., Ballen, K., Attar, E., Wang, T., Shin, J., Newton-Cheh, C., Moore, S., Sanchorawala, V., Skinner, M., Madsen, J. C., & Semigran, M. J. (2010). Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation, 90, 905–911.
3. Judge, D. P., & Johnson, N. M. (2008). Genetic evaluation of familial cardiomyopathy. Journal of Cardiovascular Translational Research, 1, 144–154.
4. Ruberg, F. L., & Berk, J. L. (2012). Transthyretin (TTR) cardiac amyloidosis. Circulation, 126, 1286–1300.
5. Merlini, G., Planté-Bordeneuve, V., Judge, D. P., Schmidt, H., Obici, L., Perlini, S., Packman, J., Tripp, T., & Grogan, D. R. (2013). Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. Journal of Cardiovascular Translational Research, 6, 1011–1020.
6. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., Munisamy, M., Falzone, R., Harrop, J., Cehelsky, J., Bettencourt, B. R., Geissler, M., Butler, J. S., Sehgal, A., Meyers, R. E., Chen, Q., Borland, T., Hutabarat, R. M., Clausen, V. A., Alvarez, R., Fitzgerald, K., Gamba-Vitalo, C., Nochur, S. V., Vaishnaw, A. K., Sah, D. W., Gollob, J. A., & Suhr, O. B. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. New England Journal of Medicine, 369, 819–829.
7. Rapezzi, C., Merlini, G., Quarta, C. C., Riva, L., Longhi, S., Leone, O., Salvi, F., Ciliberti, P., Pastorelli, F., Biagini, E., Coccolo, F., Cooke, R. M., Bacchi-Reggiani, L., Sangiorgi, D., Ferlini, A., Cavo, M., Zamagni, E., Fonte, M. L., Palladini, G., Salinaro, F., Musca, F., Obici, L., Branzi, A., & Perlini, S. (2009). Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation, 120, 1203–1212.
8. Rocken, C., & Shakespeare, A. (2002). Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch, 440, 111–122.
9. Maleszewski, J. J., Murray, D. L., Dispenzieri, A., Grogan, M., Pereira, N. L., Jenkins, S. M., Judge, D. P., Caturegli, P., Vrana, J. A., Theis, J. D., Dogan, A., & Halushka, M. K. (2013). Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovascular Pathology, 22, 189–194.
10. Collins, A. B., Smith, R. N., & Stone, J. R. (2009). Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovascular Pathology, 18, 205–216.
11. Tanskanen, M., Peuralinna, T., Polvikoski, T., Notkola, I. L., Sulkava, R., Hardy, J., Singleton, A., Kiuru-Enari, S., Paetau, A., Tienari, P. J., & Myllykangas, L. (2008). Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Annals of Medicine, 40, 232–239.
12. Wechalekar, A. D., Offer, M., Gillmore, J. D., Hawkins, P. N., & Lachmann, H. J. (2009). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nature Clinical Practice. Cardiovascular Medicine, 6, 128–133.
13. Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., & Hawkins, P. N. (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 1786–1791.
14. Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., et al. (2001). Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673–680.
15. Katzmann, J. A., Clark, R. J., Abraham, R. S., et al. (2002). Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48, 1437–1444.
16. Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., Harvey, T. C., & Drayson, M. T. (2003). Serum test for assessment of patients with Bence Jones myeloma. Lancet, 361, 489–491.
17. Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, 15, E538–E548.
18. Dispenzieri, A., Kyle, R., Merlini, G., et al. (2009). International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 23, 215–224.
19. Stone, J. R., Basso, C., Baandrup, U. T., Bruneval, P., Butany, J., Gallagher, P. J., Halushka, M. K., Miller, D. V., Padera, R. F., Radio, S. J., Sheppard, M. N., Suvarna, K., Tan, C. D., Thiene, G., van der Wal, A. C., & Veinot, J. P. (2012). Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. Cardiovascular Pathology, 21, 2–16.
20. Leone, O., Veinot, J. P., Angelini, A., Baandrup, U. T., Basso, C., Berry, G., Bruneval, P., Burke, M., Butany, J., Calabrese, F., d’Amati, G., Edwards, W. D., Fallon, J. T., Fishbein, M. C., Gallagher, P. J., Halushka, M. K., McManus, B., Pucci, A., Rodriguez, E. R., Saffitz, J., Sheppard, M. N., Steenbergen, C., Stone, J. R., Tan, C., Thiene, G., van der Wal, A. C., & Winters, G. L. (2012). Consensus statement on endomyocardial biopsy from the European Association for Cardiovascular Pathology and the Society for Cardiovascular Pathology 2011. Cardiovascular Pathology, 21, 245–274.
21. Hutchison, C. A., Harding, S., Hewins, P., Mead, G. P., Townsend, J., Bradwell, A. R., & Cockwell, P. (2008). Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology, 3, 1684–1690.
22. Tate, J., Bazeley, S., Sykes, S., & Mollee, P. (2009). Quantitative serum free light chain assay—analytical issues. Clinical Biochemistry Reviews, 30, 131–140.
23. Vermeersch, P., Vercammen, M., Holvoet, A., Vande Broek, I., Delforge, M., & Bossuyt, X. (2009). Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders. Clinica Chimica Acta, 410, 54–58.
24. Bokhari, S., Castaño, A., Pozniakoff, T., Deslisle, S., Latif, F., & Maurer, M. S. (2013). 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circulation. Cardiovascular Imaging, 6, 195–201.